Developing new pain relief medications targeting specific receptors
Planning Study for the Development of Sigma 2 ligands as Analgesics
This study is looking at natural substances from cyanobacteria to find new pain relief medications that work by targeting a specific receptor involved in managing pain, and it's designed for people who suffer from chronic pain.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10641500 on NIH RePORTER |
What this research studies
This research focuses on creating new medications for chronic pain by exploring natural products derived from cyanobacteria. The team aims to target a specific receptor known as sigma 2/transmembrane protein 97 (σ-2/TMEM97), which has recently been identified as playing a role in pain modulation. By studying the effects of these natural products on pain receptors in laboratory settings, the researchers hope to develop effective analgesics. The project involves collaboration among scientists from various fields to ensure a comprehensive approach to drug development.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing chronic neuropathic pain who are seeking new treatment options.
Not a fit: Patients with acute pain or those who do not have chronic pain conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel pain relief medications that are more effective for patients suffering from chronic pain.
How similar studies have performed: Other research has shown promise in targeting similar receptors for pain relief, indicating that this approach could be a viable path for developing new analgesics.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Tidgewell, Kevin Joseph — University of Kentucky
- Study coordinator: Tidgewell, Kevin Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.